Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Splenic Artery Aneurysms, A Rare Complication of Type 1 Gaucher Disease: Report of Five Cases.

Serratrice C, Cox TM, Leguy-Seguin V, Morris E, Yousfi K, Monnet O, Sibert A, Allaham W, Belmatoug N.

J Clin Med. 2019 Feb 8;8(2). pii: E219. doi: 10.3390/jcm8020219.

2.

[Gaucher disease: A review].

Nguyen Y, Stirnemann J, Belmatoug N.

Rev Med Interne. 2019 May;40(5):313-322. doi: 10.1016/j.revmed.2018.11.012. Epub 2019 Jan 11. French.

PMID:
30638965
3.

Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.

Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, Zimran A.

Intern Med J. 2019 May;49(5):578-591. doi: 10.1111/imj.14156.

PMID:
30414226
4.

[The value of fecal calprotectin assay in chronic panniculitis of unknown etiology].

Kaddour K, Lemasson J, Haettich-Pialoux B, Guedj N, Belmatoug N, Treton X, Becheur H, Fantin B, Descamps V, Le Bozec P.

Ann Dermatol Venereol. 2018 Nov;145(11):702-705. doi: 10.1016/j.annder.2018.07.018. Epub 2018 Sep 25. French. No abstract available.

PMID:
30266304
5.

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG.

Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8.

PMID:
30128966
6.

Transition from pediatric to adult care in adolescents with hereditary metabolic diseases: Specific guidelines from the French network for rare inherited metabolic diseases (G2M).

Chabrol B, Jacquin P, Francois L, Broué P, Dobbelaere D, Douillard C, Dubois S, Feillet F, Perrier A, Fouilhoux A, Labarthe F, Lamireau D, Mazodier K, Maillot F, Mochel F, Schiff M, Belmatoug N.

Arch Pediatr. 2018 Jun 15. pii: S0929-693X(18)30115-5. doi: 10.1016/j.arcped.2018.05.009. [Epub ahead of print]

PMID:
29914755
7.

Hepatocellular carcinoma in Gaucher disease: an international case series.

Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM.

J Inherit Metab Dis. 2018 Sep;41(5):819-827. doi: 10.1007/s10545-018-0142-y. Epub 2018 Feb 8.

8.

Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological Findings.

Bremova-Ertl T, Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T, Bardins S, Frenzel C, Malinová V, Naumann S, Arndt J, Mengel E, Reinke J, Strobl R, Strupp M.

Front Neurol. 2018 Jan 15;8:711. doi: 10.3389/fneur.2017.00711. eCollection 2017.

9.

Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease.

Lefebvre T, Reihani N, Daher R, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Puy H, Le Van Kim C, Franco M, Karim Z.

Haematologica. 2018 Apr;103(4):587-596. doi: 10.3324/haematol.2017.177816. Epub 2018 Jan 5.

10.

Pyogenic vertebral osteomyelitis of the elderly: Characteristics and outcomes.

Courjon J, Lemaignen A, Ghout I, Therby A, Belmatoug N, Dinh A, Gras G, Bernard L; DTS (Duration of Treatment for Spondylodiscitis) study group.

PLoS One. 2017 Dec 5;12(12):e0188470. doi: 10.1371/journal.pone.0188470. eCollection 2017.

11.

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS).

Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D, Giraldo P, Goker-Alpan O, Lau H, Lukina E, Panahloo Z, Schwartz IVD; GOS Study group.

Am J Hematol. 2018 Feb;93(2):205-212. doi: 10.1002/ajh.24957. Epub 2017 Dec 12.

12.

Optimization of ultra-high pressure liquid chromatography - tandem mass spectrometry determination in plasma and red blood cells of four sphingolipids and their evaluation as biomarker candidates of Gaucher's disease.

Chipeaux C, de Person M, Burguet N, Billette de Villemeur T, Rose C, Belmatoug N, Héron S, Le Van Kim C, Franco M, Moussa F.

J Chromatogr A. 2017 Nov 24;1525:116-125. doi: 10.1016/j.chroma.2017.10.038. Epub 2017 Oct 14.

PMID:
29061473
13.

Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians.

Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D.

Mol Genet Metab. 2017 Nov;122(3):122-129. doi: 10.1016/j.ymgme.2017.08.002. Epub 2017 Aug 4.

14.

Type 3 Gaucher disease, diagnostic in adulthood.

Detollenaere C, Benghergbia M, Brassier A, de Villemeur TB, Amsallem D, Berger M, Stirnemann J, Belmatoug N, Rose C.

Mol Genet Metab Rep. 2017 Jul 11;13:1-2. doi: 10.1016/j.ymgmr.2017.07.002. eCollection 2017 Dec. No abstract available.

15.

Effect of velaglucerase alfa enzyme replacement therapy on red blood cell properties in Gaucher disease.

Franco M, Reihani N, Marin M, De Person M, Billette de Villemeur T, Rose C, Colin Y, Moussa F, Belmatoug N, Le Van Kim C.

Am J Hematol. 2017 Sep;92(9):E561-E563. doi: 10.1002/ajh.24816. Epub 2017 Jul 19. No abstract available.

16.

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM.

Blood Cells Mol Dis. 2018 Feb;68:203-208. doi: 10.1016/j.bcmd.2016.10.008. Epub 2016 Oct 24.

17.

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG.

Int J Mol Sci. 2017 Feb 17;18(2). pii: E441. doi: 10.3390/ijms18020441. Review.

18.

Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.

El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.

Mol Genet Metab. 2017 Jan - Feb;120(1-2):47-56. doi: 10.1016/j.ymgme.2016.12.001. Epub 2016 Dec 6.

19.

Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjects.

Serratrice C, Bensalah N, Penaranda G, Bardin N, Belmatoug N, Masseau A, Rose C, Lidove O, Camou F, Maillot F, Leguy V, Magy-Bertrand N, Marie I, Cherin P, Bengherbia M, Carballo S, Boucraut J, Serratrice J, Berger M, Verrot D.

Joint Bone Spine. 2018 Jan;85(1):71-77. doi: 10.1016/j.jbspin.2016.12.002. Epub 2016 Dec 26.

PMID:
28034821
20.

[Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: A retrospective multicentric study of 28 adult cases].

Lidove O, Belmatoug N, Froissart R, Lavigne C, Durieu I, Mazodier K, Serratrice C, Douillard C, Goizet C, Cathebras P, Besson G, Amoura Z, Tazi A, Gatfossé M, Rivière S, Sené T, Vanier MT, Ziza JM.

Rev Med Interne. 2017 May;38(5):291-299. doi: 10.1016/j.revmed.2016.10.387. Epub 2016 Nov 22. French.

PMID:
27884455
21.

Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey.

Lau H, Belmatoug N, Deegan P, Goker-Alpan O, Schwartz IVD, Shankar SP, Panahloo Z, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:226-231. doi: 10.1016/j.bcmd.2016.10.003. Epub 2016 Oct 20.

22.

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM.

Eur J Intern Med. 2017 Jan;37:25-32. doi: 10.1016/j.ejim.2016.07.011. Epub 2016 Aug 10. Review.

23.

Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Reihani N, Arlet JB, Dussiot M, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Hermine O, Le Van Kim C, Franco M.

Haematologica. 2016 Dec;101(12):1489-1498. Epub 2016 Jul 28.

24.

Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.

Hollak CE, Biegstraaten M, Baumgartner MR, Belmatoug N, Bembi B, Bosch A, Brouwers M, Dekker H, Dobbelaere D, Engelen M, Groenendijk MC, Lachmann R, Langendonk JG, Langeveld M, Linthorst G, Morava E, Poll-The BT, Rahman S, Rubio-Gozalbo ME, Spiekerkoetter U, Treacy E, Wanders R, Zschocke J, Hagendijk R.

Orphanet J Rare Dis. 2016 Jan 25;11:7. doi: 10.1186/s13023-016-0383-5.

25.

Understanding the natural history of Gaucher disease.

Mistry PK, Belmatoug N, vom Dahl S, Giugliani R.

Am J Hematol. 2015 Jul;90 Suppl 1:S6-11. doi: 10.1002/ajh.24055. Review.

26.

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.

Orphanet J Rare Dis. 2015 May 13;10:62. doi: 10.1186/s13023-015-0275-0.

27.

Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo JD, Petrover D.

Eur Radiol. 2015 Oct;25(10):2969-75. doi: 10.1007/s00330-015-3715-2. Epub 2015 Apr 16.

PMID:
25875285
28.

[Acid sphingomyelinase deficiency and spleen trauma: splenectomy or not splenectomy?].

Lidove O, Le Fèvre L, Goasguen N, Jamali M, Vercellino L, Garnier M, Khellaf M, Belmatoug N, Ziza JM.

Rev Med Interne. 2015 Sep;36(9):619-22. doi: 10.1016/j.revmed.2014.10.367. Epub 2014 Nov 5. French.

PMID:
25479761
29.

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.

Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D; Duration of Treatment for Spondylodiscitis (DTS) study group.

Lancet. 2015 Mar 7;385(9971):875-82. doi: 10.1016/S0140-6736(14)61233-2. Epub 2014 Nov 5.

PMID:
25468170
30.

Behcet's disease in Budd-Chiari syndrome.

Desbois AC, Rautou PE, Biard L, Belmatoug N, Wechsler B, Resche-Rigon M, Zarrouk V, Fantin B, de Chambrun MP, Cacoub P, Valla D, Saadoun D, Plessier A.

Orphanet J Rare Dis. 2014 Sep 13;9:104. doi: 10.1186/s13023-014-0153-1. eCollection 2014.

31.

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.

Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, Belmatoug N, Mentré F.

Orphanet J Rare Dis. 2014 Jun 30;9:95. doi: 10.1186/1750-1172-9-95.

32.

Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.

Serratrice C, Bengherbia M, Alessandrini M, Grosbois B, Camou F, Pers YM, Bismuth M, Marie I, Belmatoug N, Berger M; Comité d'Evaluation et de Traitement de la maladie de Gaucher.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):94-6. doi: 10.1016/j.bcmd.2013.12.004. Epub 2014 Jan 7. No abstract available.

PMID:
24411065
33.

A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Lecourt S, Mouly E, Freida D, Cras A, Ceccaldi R, Heraoui D, Chomienne C, Marolleau JP, Arnulf B, Porcher R, Caillaud C, Vanneaux V, Belmatoug N, Larghero J.

PLoS One. 2013 Jul 25;8(7):e69293. doi: 10.1371/journal.pone.0069293. Print 2013.

34.

Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.

Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A.

Blood Cells Mol Dis. 2013 Aug;51(2):116-24. doi: 10.1016/j.bcmd.2013.04.005. Epub 2013 May 14.

PMID:
23683771
35.

Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease.

Franco M, Collec E, Connes P, van den Akker E, Billette de Villemeur T, Belmatoug N, von Lindern M, Ameziane N, Hermine O, Colin Y, Le Van Kim C, Mignot C.

Blood. 2013 Jan 17;121(3):546-55. doi: 10.1182/blood-2012-07-442467. Epub 2012 Dec 3.

36.

The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.

Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, Rose C, Camou F, de Roux-Serratrice C, Grosbois B, Kaminsky P, Robert A, Caillaud C, Froissart R, Levade T, Masseau A, Mignot C, Sedel F, Dobbelaere D, Vanier MT, Valayanopoulos V, Fain O, Fantin B, de Villemeur TB, Mentré F, Belmatoug N.

Orphanet J Rare Dis. 2012 Oct 9;7:77. doi: 10.1186/1750-1172-7-77.

37.

Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.

Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.

Br J Haematol. 2012 Aug;158(4):528-38. doi: 10.1111/j.1365-2141.2012.09175.x. Epub 2012 May 29.

PMID:
22640238
38.

Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment.

Mekinian A, Stirnemann J, Belmatoug N, Heraoui D, Fantin B, Fain O, Charpentier A, Rose C.

Blood Cells Mol Dis. 2012 Jun 15;49(1):53-7. doi: 10.1016/j.bcmd.2012.04.002. Epub 2012 May 3.

PMID:
22560483
39.

The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.

Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, Froissart R, Rapatel C, Rose C, Belmatoug N, Berger MG.

Br J Haematol. 2012 Apr;157(2):274-7. doi: 10.1111/j.1365-2141.2011.08989.x. Epub 2012 Jan 9. No abstract available.

PMID:
22224474
40.

Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency.

Lecourt S, Vanneaux V, Cras A, Freida D, Heraoui D, Herbi L, Caillaud C, Chomienne C, Marolleau JP, Belmatoug N, Larghero J.

Stem Cells Dev. 2012 Jan 20;21(2):239-48. doi: 10.1089/scd.2011.0365. Epub 2011 Oct 18.

PMID:
21867425
41.

Retroperitoneal abscesses due to Nocardia farcinica: report of two cases in patients with malnutrition.

de Montmollin E, Corcos O, Noussair L, Leflon-Guibout V, Belmatoug N, Joly F, Lefort A.

Infection. 2012 Feb;40(1):93-6. doi: 10.1007/s15010-011-0176-7. Epub 2011 Aug 23. No abstract available.

PMID:
21861123
42.

Gastrointestinal disturbances and their management in miglustat-treated patients.

Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Pastores GM.

J Inherit Metab Dis. 2011 Oct;34(5):991-1001. doi: 10.1007/s10545-011-9368-7. Epub 2011 Jul 21. Review.

PMID:
21779792
43.

[Gaucher disease].

Stirnemann J, de Villemeur TB, Heraoui D, Belmatoug N; Comité d'évaluation du traitement de la maladie de Gaucher.

Rev Prat. 2011 Feb;61(2):165-8. French. No abstract available.

PMID:
21618759
44.

The management of pregnancy in Gaucher disease.

Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A.

Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):3-8. doi: 10.1016/j.ejogrb.2010.12.024. Epub 2011 Jan 26. Review.

PMID:
21269752
45.

Early access experience with VPRIV(®): recommendations for 'core data' collection.

Hughes DA, Al-Sayed M, Belmatoug N, Bodamer O, Böttcher T, Cappellini M, Cohen IJ, Eagleton T, Elstein D, Giraldo P, Jones S, Kaplinsky C, Lund A, Machaczka M, Mengel E, Pastores GM, Rosenbaum H, Sjo M, Tiling N, Tsaftaridis P, Zimran A, Weinreb N.

Blood Cells Mol Dis. 2011 Aug 15;47(2):140-2. doi: 10.1016/j.bcmd.2010.10.015. Epub 2010 Dec 13. No abstract available.

PMID:
21146428
46.

Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.

Stirnemann J, Boutten A, Vincent C, Mekinian A, Heraoui D, Fantin B, Fain O, Mentré F, Belmatoug N.

Blood Cells Mol Dis. 2011 Jan 15;46(1):34-8. doi: 10.1016/j.bcmd.2010.10.014. Epub 2010 Nov 16.

PMID:
21084203
47.

Bone events and evolution of biologic markers in Gaucher disease before and during treatment.

Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentré F.

Arthritis Res Ther. 2010;12(4):R156. doi: 10.1186/ar3111. Epub 2010 Aug 9.

48.

Bone involvement as presenting sign of pediatric-onset Gaucher disease.

Rossi L, Zulian F, Stirnemann J, Billette de Villemur T, Belmatoug N.

Joint Bone Spine. 2011 Jan;78(1):70-4. doi: 10.1016/j.jbspin.2010.02.045.

PMID:
20627654
49.

A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients.

Kraoua I, Sedel F, Caillaud C, Froissart R, Stirnemann J, Chaurand G, Flodrops H, Tari S, Gourfinkel-An I, Mathieu S, Belmatoug N, Billette de Villemeur T, Mignot C.

Brain Dev. 2011 Feb;33(2):131-9. doi: 10.1016/j.braindev.2010.02.005. Epub 2010 Mar 21.

PMID:
20307947
50.

[Home therapy in Gaucher disease].

Belmatoug N, Mamine S; Comité d'Evaluation du Traitement de la maladie de Gaucher.

Presse Med. 2009 Dec;38 Suppl 2:2S46-9. doi: 10.1016/S0755-4982(09)73669-3. Review. French. No abstract available.

PMID:
20304306

Supplemental Content

Loading ...
Support Center